Phase III STAND trial

Novartis provides update on Phase III STAND trial assessing crizanlizumab The preliminary results from the ongoing global phase III study STAND indicate no statistically significant difference between crizanlizumab 5mg/kg or crizanlizumab 7.5mg/kg and placebo in annualized rates of vaso-occlusive crises (pain crises) leading to a healthcare visit over the first-year post randomization. These findings are […]